Fig. 6.
Effect of Nrf2 activator compounds on HMOX1, SOD1 and TXNRD1 mRNA expression in alveolar macrophage from S and COPD patients. Alveolar macrophages from COPD patients and S were treated with CDDO (0.3–100 nM), GSK7 (1–10,00 nM), C4X_6665 (0.3–30 nM), Sulforaphane (1000–10,000 nM), MMF 1000–10,000 nM) or vehicle control (DMSO) for 24 h for qPCR. HMOX1 (n = 8 COPD and n = 8 S) (A and B, respectively), SOD1 (n = 8 COPD and n = 6 S) (C and D, respectively) and TXNRD1 (n = 8 COPD and n = 6 S) (E and F, respectively) mRNA expression was assessed by RT-qPCR. Data presented as mean ± SEM fold increase above DMSO control (RT-qPCR data 2−ΔΔCt). *, **, *** = significantly above DMSO control (p < 0.05, p < 0.01 and p < 0.001, respectively)